Abeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) CEO Vishwas Seshadri sold 25,000 shares of the business's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $4.78, for a total transaction of $119,500.00. Following the sale, the chief executive officer now directly owns 1,355,322 shares of the company's stock, valued at $6,478,439.16. This represents a 1.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Abeona Therapeutics Stock Down 8.7 %
Shares of NASDAQ:ABEO traded down $0.43 during trading hours on Friday, hitting $4.52. The company's stock had a trading volume of 745,786 shares, compared to its average volume of 422,455. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The firm's fifty day moving average price is $5.36 and its 200 day moving average price is $5.78. Abeona Therapeutics Inc has a 52 week low of $3.05 and a 52 week high of $8.45. The company has a market capitalization of $219.37 million, a price-to-earnings ratio of -1.68 and a beta of 1.70.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.19. As a group, research analysts expect that Abeona Therapeutics Inc will post -1.16 EPS for the current year.
Institutional Investors Weigh In On Abeona Therapeutics
A number of hedge funds have recently made changes to their positions in ABEO. Adage Capital Partners GP L.L.C. raised its holdings in Abeona Therapeutics by 20.1% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company's stock worth $21,736,000 after purchasing an additional 652,366 shares in the last quarter. Western Standard LLC raised its stake in shares of Abeona Therapeutics by 22.8% during the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company's stock worth $11,610,000 after acquiring an additional 386,321 shares in the last quarter. 683 Capital Management LLC lifted its position in Abeona Therapeutics by 17.3% during the fourth quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company's stock valued at $4,411,000 after acquiring an additional 116,845 shares during the last quarter. Citigroup Inc. boosted its stake in Abeona Therapeutics by 10.1% in the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company's stock valued at $3,897,000 after acquiring an additional 56,332 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Abeona Therapeutics by 21.7% in the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company's stock valued at $2,942,000 after acquiring an additional 83,050 shares in the last quarter. 80.56% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research firms have issued reports on ABEO. StockNews.com raised shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, March 24th. Oppenheimer initiated coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price target for the company. Finally, HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Abeona Therapeutics in a report on Monday, March 24th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $17.50.
View Our Latest Analysis on ABEO
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
See Also
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
